After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Q4 2024 Management View CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

On January 29, 2025, the CAFC issued opinions affirming the preliminary injunctions issued against biosimilars of Regeneron’s EYLEA® ...

particularly the Eylea HD, has promising developments with a pre-filled syringe application on track for a mid-2025 US launch. This positions it to compete effectively against Roche’s Vabysmo ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14.

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

Eylea (aflibercept) is a prescription drug that treats certain eye conditions. Eylea can cause side effects that range from mild to serious. An example includes cataracts, which may become a long ...